Fourthly, a considerable gap in delamanid treatment between parent Trial 204 and extension Trial 208 occurred for some patients.
Peter Kim, Merck's head of research, told analysts that the company still did not have data from the continuing extension trial.
OFA111752 was a phase II extension trial with a 130-week open-label period and safety follow-up [16].
Patients from REVEAL could enter an open-label extension trial to receive adalimumab for approximately 3 years of total therapy.
Likewise, low levels of flexor muscle stimulation often occurred during extension trials (see the single extension trial in Figure 3 and Figure 6B, red curve).
No formal sample size calculation was performed for the extension trial; the extension trial was open to all patients who were eligible to participate.
Patients randomized to placebo who experienced disease flares were eligible for an open-label extension trial.
Data from an open-label, long-term extension trial were recently reported.
During the extension trial, patients continued to receive diet and exercise counselling based on local recommendations.
The stability of clobazam dosing over time was carefully monitored in this open-label extension trial.
This was a phase IIb, randomized, active-controlled, open-label extension trial.
